Logo image of TECX

TECTONIC THERAPEUTIC INC (TECX) Stock Fundamental Analysis

USA - NASDAQ:TECX - US8789721086 - Common Stock

18.62 USD
+0.74 (+4.14%)
Last: 10/29/2025, 8:02:06 PM
23.4999 USD
+4.88 (+26.21%)
Pre-Market: 10/30/2025, 8:24:04 AM
Fundamental Rating

2

Overall TECX gets a fundamental rating of 2 out of 10. We evaluated TECX against 534 industry peers in the Biotechnology industry. While TECX seems to be doing ok healthwise, there are quite some concerns on its profitability. TECX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TECX had negative earnings in the past year.
In the past year TECX has reported a negative cash flow from operations.
In the past 5 years TECX always reported negative net income.
TECX had a negative operating cash flow in each of the past 5 years.
TECX Yearly Net Income VS EBIT VS OCF VS FCFTECX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of TECX (-22.34%) is better than 75.28% of its industry peers.
With an excellent Return On Equity value of -23.25%, TECX belongs to the best of the industry, outperforming 82.58% of the companies in the same industry.
Industry RankSector Rank
ROA -22.34%
ROE -23.25%
ROIC N/A
ROA(3y)-71.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TECX Yearly ROA, ROE, ROICTECX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TECX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TECX Yearly Profit, Operating, Gross MarginsTECX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

The number of shares outstanding for TECX has been increased compared to 1 year ago.
TECX has a better debt/assets ratio than last year.
TECX Yearly Shares OutstandingTECX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 5M 10M
TECX Yearly Total Debt VS Total AssetsTECX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

TECX has an Altman-Z score of 17.53. This indicates that TECX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 17.53, TECX belongs to the best of the industry, outperforming 88.95% of the companies in the same industry.
TECX has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
TECX's Debt to Equity ratio of 0.00 is in line compared to the rest of the industry. TECX outperforms 50.19% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 17.53
ROIC/WACCN/A
WACCN/A
TECX Yearly LT Debt VS Equity VS FCFTECX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

TECX has a Current Ratio of 25.60. This indicates that TECX is financially healthy and has no problem in meeting its short term obligations.
TECX has a better Current ratio (25.60) than 97.00% of its industry peers.
A Quick Ratio of 25.60 indicates that TECX has no problem at all paying its short term obligations.
TECX's Quick ratio of 25.60 is amongst the best of the industry. TECX outperforms 97.00% of its industry peers.
Industry RankSector Rank
Current Ratio 25.6
Quick Ratio 25.6
TECX Yearly Current Assets VS Current LiabilitesTECX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 55.01% over the past year.
EPS 1Y (TTM)55.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 8.98% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y47.97%
EPS Next 2Y18.5%
EPS Next 3Y8.98%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TECX Yearly EPS VS EstimatesTECX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -10 -20 -30 -40

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TECX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TECX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TECX Price Earnings VS Forward Price EarningsTECX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TECX Per share dataTECX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.5%
EPS Next 3Y8.98%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TECX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TECTONIC THERAPEUTIC INC

NASDAQ:TECX (10/29/2025, 8:02:06 PM)

Premarket: 23.4999 +4.88 (+26.21%)

18.62

+0.74 (+4.14%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-06 2025-11-06/bmo
Inst Owners65%
Inst Owner Change0%
Ins Owners27.25%
Ins Owner Change0.69%
Market Cap348.38M
Revenue(TTM)N/A
Net Income(TTM)-65980000
Analysts84
Price Target81.35 (336.9%)
Short Float %30.82%
Short Ratio7.27
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.84%
Min EPS beat(2)-6.86%
Max EPS beat(2)16.54%
EPS beat(4)2
Avg EPS beat(4)1.92%
Min EPS beat(4)-42.6%
Max EPS beat(4)40.61%
EPS beat(8)4
Avg EPS beat(8)-15.91%
EPS beat(12)5
Avg EPS beat(12)-43.44%
EPS beat(16)7
Avg EPS beat(16)-32.91%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-4.61%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.45%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.34%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.23
P/tB 1.23
EV/EBITDA N/A
EPS(TTM)-4.04
EYN/A
EPS(NY)-4.87
Fwd EYN/A
FCF(TTM)-3.44
FCFYN/A
OCF(TTM)-3.43
OCFYN/A
SpS0
BVpS15.17
TBVpS15.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.34%
ROE -23.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-71.59%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.21%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 25.6
Quick Ratio 25.6
Altman-Z 17.53
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)78.64%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%75.35%
EPS Next Y47.97%
EPS Next 2Y18.5%
EPS Next 3Y8.98%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-34.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-22.46%
EBIT Next 3Y-17.63%
EBIT Next 5YN/A
FCF growth 1Y-44.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.23%
OCF growth 3YN/A
OCF growth 5YN/A

TECTONIC THERAPEUTIC INC / TECX FAQ

What is the fundamental rating for TECX stock?

ChartMill assigns a fundamental rating of 2 / 10 to TECX.


What is the valuation status for TECX stock?

ChartMill assigns a valuation rating of 0 / 10 to TECTONIC THERAPEUTIC INC (TECX). This can be considered as Overvalued.


How profitable is TECTONIC THERAPEUTIC INC (TECX) stock?

TECTONIC THERAPEUTIC INC (TECX) has a profitability rating of 1 / 10.


How financially healthy is TECTONIC THERAPEUTIC INC?

The financial health rating of TECTONIC THERAPEUTIC INC (TECX) is 6 / 10.


What is the expected EPS growth for TECTONIC THERAPEUTIC INC (TECX) stock?

The Earnings per Share (EPS) of TECTONIC THERAPEUTIC INC (TECX) is expected to grow by 47.97% in the next year.